Key result
IV furosemide plus hypertonic saline drives ~4x greater NT-proBNP reduction vs furosemide alone in ADHF.
Why the study?
Does intravenous furosemide plus hypertonic saline solution improve inflammatory, remodeling markers, and epigenetic signatures in adults with acute decompensated heart failure?
RCT (n=200)
Single-blind
Computer-generated random sequence (1:1)
No
Does intravenous furosemide plus hypertonic saline solution improve inflammatory, remodeling markers, and epigenetic signatures in adults with acute decompensated heart failure?
Adding small-volume hypertonic saline to intravenous furosemide in acute decompensated heart failure favorably modulates inflammatory and remodeling biomarkers as well as epigenetic signatures compared to furosemide alone.
Answers are grounded in this paper and cite their sources.
May warrant hypertonic saline plus furosemide in acute decompensated HF; extends evidence for beneficial effects on inflammatory, remodeling, and epigenetic signatures.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Daidone et al. (2026) conducted an RCT in Acute decompensated heart failure (ADHF) with reduced ejection fraction (HFrEF) (n=200). Intravenous furosemide plus hypertonic saline solution (HSS) vs. Intravenous furosemide alone (120-250 mg twice daily) was evaluated on Reduction in serum levels of heart failure markers (NT-proBNP delta) (p=<0.0005). Intravenous furosemide plus hypertonic saline reduced NT-proBNP compared to furosemide alone in patients with acute decompensated heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: